These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23569308

  • 1. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.
    J Clin Oncol; 2013 May 10; 31(14):1740-7. PubMed ID: 23569308
    [Abstract] [Full Text] [Related]

  • 2. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA, Nathan F, Taboada M, Morris T, Hubner A.
    Prostate; 2011 Sep 10; 71(12):1264-75. PubMed ID: 21271613
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators.
    Lancet; 2010 Oct 02; 376(9747):1147-54. PubMed ID: 20888992
    [Abstract] [Full Text] [Related]

  • 7. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M, VENICE investigators.
    Lancet Oncol; 2013 Jul 02; 14(8):760-8. PubMed ID: 23742877
    [Abstract] [Full Text] [Related]

  • 8. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov 02; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA.
    J Clin Oncol; 2010 Sep 20; 28(27):4247-54. PubMed ID: 20733135
    [Abstract] [Full Text] [Related]

  • 10. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
    Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R.
    J Clin Oncol; 2015 Mar 01; 33(7):723-31. PubMed ID: 25624429
    [Abstract] [Full Text] [Related]

  • 11. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators.
    J Clin Oncol; 2007 Feb 20; 25(6):669-74. PubMed ID: 17308271
    [Abstract] [Full Text] [Related]

  • 12. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
    Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M.
    J Clin Oncol; 2009 Nov 10; 27(32):5431-8. PubMed ID: 19805692
    [Abstract] [Full Text] [Related]

  • 13. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.
    Clin Cancer Res; 2008 Oct 01; 14(19):6270-6. PubMed ID: 18829508
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.
    Lancet Oncol; 2015 Apr 01; 16(4):417-25. PubMed ID: 25743937
    [Abstract] [Full Text] [Related]

  • 15. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I.
    J Clin Oncol; 2014 Jan 10; 32(2):76-82. PubMed ID: 24323035
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 10; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 17. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K.
    Gynecol Oncol; 2013 Jul 10; 130(1):31-7. PubMed ID: 23234805
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.
    Anticancer Res; 2012 Feb 10; 32(2):633-41. PubMed ID: 22287756
    [Abstract] [Full Text] [Related]

  • 19. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C.
    Lancet Oncol; 2013 Nov 10; 14(12):1193-9. PubMed ID: 24075621
    [Abstract] [Full Text] [Related]

  • 20. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
    Qi P, Chen M, Zhang LX, Song RX, He ZH, Wang ZP.
    PLoS One; 2015 Nov 10; 10(7):e0133803. PubMed ID: 26192308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.